 Thomas Beresford
Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 18 | 2023 | 717 | 3.970 |
Why?
| | Alcohol Deterrents | 6 | 2007 | 15 | 1.570 |
Why?
| | Disulfiram | 6 | 2007 | 12 | 1.560 |
Why?
| | Immunosuppressive Agents | 4 | 2019 | 683 | 1.500 |
Why?
| | Cyclosporine | 3 | 2018 | 173 | 1.260 |
Why?
| | Calcineurin | 3 | 2019 | 95 | 1.220 |
Why?
| | Cocaine-Related Disorders | 4 | 2017 | 107 | 1.110 |
Why?
| | Alcohol Drinking | 5 | 2018 | 652 | 1.110 |
Why?
| | Defense Mechanisms | 3 | 2014 | 23 | 1.040 |
Why?
| | Alcohol-Related Disorders | 4 | 2014 | 111 | 0.970 |
Why?
| | Antipsychotic Agents | 3 | 2017 | 193 | 0.890 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2018 | 87 | 0.860 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2023 | 157 | 0.860 |
Why?
| | Aripiprazole | 3 | 2017 | 18 | 0.850 |
Why?
| | Cost of Illness | 2 | 2014 | 258 | 0.830 |
Why?
| | Liver Transplantation | 4 | 2018 | 847 | 0.730 |
Why?
| | Nervous System Diseases | 2 | 2019 | 261 | 0.640 |
Why?
| | Perphenazine | 1 | 2017 | 1 | 0.640 |
Why?
| | Schizophrenia | 2 | 2017 | 501 | 0.630 |
Why?
| | Dopamine Agents | 1 | 2017 | 14 | 0.630 |
Why?
| | Craving | 1 | 2017 | 33 | 0.620 |
Why?
| | Brain Injuries, Traumatic | 1 | 2022 | 318 | 0.590 |
Why?
| | Ego | 2 | 2006 | 10 | 0.560 |
Why?
| | Jurisprudence | 2 | 2005 | 14 | 0.510 |
Why?
| | Cannabinoids | 1 | 2015 | 115 | 0.480 |
Why?
| | Hepatitis C | 3 | 2007 | 217 | 0.480 |
Why?
| | Substance Abuse Treatment Centers | 2 | 2005 | 42 | 0.480 |
Why?
| | Ethanol | 4 | 2023 | 575 | 0.470 |
Why?
| | Models, Psychological | 1 | 2014 | 298 | 0.420 |
Why?
| | Hippocampus | 2 | 2006 | 735 | 0.420 |
Why?
| | Brain | 2 | 2015 | 2490 | 0.420 |
Why?
| | Psychotherapy | 1 | 2014 | 177 | 0.420 |
Why?
| | Patient Compliance | 3 | 2007 | 537 | 0.410 |
Why?
| | Tacrolimus | 1 | 2012 | 151 | 0.390 |
Why?
| | Sirolimus | 1 | 2012 | 195 | 0.380 |
Why?
| | Neurology | 1 | 2010 | 94 | 0.350 |
Why?
| | Cannabis | 1 | 2015 | 382 | 0.340 |
Why?
| | Inflammation | 1 | 2019 | 2571 | 0.330 |
Why?
| | Humans | 39 | 2023 | 119032 | 0.320 |
Why?
| | Stearates | 1 | 2007 | 1 | 0.300 |
Why?
| | Double-Blind Method | 4 | 2022 | 1687 | 0.300 |
Why?
| | Palmitic Acids | 1 | 2007 | 9 | 0.300 |
Why?
| | Oleic Acids | 1 | 2007 | 13 | 0.300 |
Why?
| | Behavior, Addictive | 1 | 2007 | 77 | 0.290 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2006 | 9 | 0.290 |
Why?
| | Bipolar Disorder | 5 | 2006 | 209 | 0.280 |
Why?
| | Sick Role | 1 | 2006 | 19 | 0.280 |
Why?
| | Serum Albumin | 1 | 2007 | 147 | 0.280 |
Why?
| | Valproic Acid | 2 | 2022 | 44 | 0.270 |
Why?
| | Physician-Patient Relations | 1 | 2010 | 489 | 0.270 |
Why?
| | Depressive Disorder, Major | 2 | 2020 | 303 | 0.270 |
Why?
| | Mental Disorders | 1 | 2014 | 939 | 0.270 |
Why?
| | Food Handling | 2 | 2016 | 48 | 0.270 |
Why?
| | Anxiety Disorders | 2 | 2005 | 309 | 0.260 |
Why?
| | Hydrocortisone | 1 | 2006 | 273 | 0.250 |
Why?
| | Middle Aged | 19 | 2017 | 27627 | 0.250 |
Why?
| | Male | 25 | 2018 | 57818 | 0.250 |
Why?
| | Administration, Sublingual | 1 | 2004 | 14 | 0.250 |
Why?
| | Mood Disorders | 1 | 2005 | 119 | 0.240 |
Why?
| | Quinolones | 1 | 2005 | 98 | 0.240 |
Why?
| | Teaching | 1 | 2005 | 236 | 0.230 |
Why?
| | Anticonvulsants | 1 | 2005 | 184 | 0.230 |
Why?
| | Diagnosis, Dual (Psychiatry) | 2 | 2017 | 36 | 0.220 |
Why?
| | Cocaine | 2 | 2009 | 158 | 0.220 |
Why?
| | Piperazines | 1 | 2005 | 316 | 0.220 |
Why?
| | Postoperative Care | 1 | 2004 | 237 | 0.220 |
Why?
| | Signal Transduction | 1 | 2015 | 4713 | 0.210 |
Why?
| | Psychiatry | 1 | 2005 | 201 | 0.210 |
Why?
| | Adult | 18 | 2017 | 31525 | 0.210 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 1947 | 0.210 |
Why?
| | Adaptation, Psychological | 1 | 2006 | 557 | 0.200 |
Why?
| | Learning | 1 | 2005 | 374 | 0.200 |
Why?
| | Irritable Mood | 1 | 2022 | 51 | 0.200 |
Why?
| | Prognosis | 3 | 2018 | 3443 | 0.200 |
Why?
| | Depressive Disorder, Treatment-Resistant | 1 | 2020 | 4 | 0.200 |
Why?
| | Lactobacillus helveticus | 2 | 2009 | 2 | 0.180 |
Why?
| | Animals | 8 | 2019 | 33399 | 0.180 |
Why?
| | Brain Injuries | 1 | 2005 | 484 | 0.180 |
Why?
| | Antidepressive Agents | 2 | 2020 | 189 | 0.180 |
Why?
| | Psychiatric Status Rating Scales | 3 | 2006 | 499 | 0.170 |
Why?
| | DNA Transposable Elements | 2 | 2009 | 102 | 0.170 |
Why?
| | Mice, Inbred C57BL | 3 | 2018 | 4914 | 0.170 |
Why?
| | Cheese | 2 | 2016 | 5 | 0.160 |
Why?
| | Female | 20 | 2017 | 61588 | 0.160 |
Why?
| | Alcohol Abstinence | 1 | 2018 | 10 | 0.160 |
Why?
| | Injections, Intraventricular | 1 | 2018 | 73 | 0.160 |
Why?
| | Injections, Intraperitoneal | 1 | 2018 | 108 | 0.160 |
Why?
| | Binge-Eating Disorder | 1 | 2018 | 19 | 0.160 |
Why?
| | Neuroimmunomodulation | 1 | 2018 | 72 | 0.160 |
Why?
| | Depression | 1 | 2006 | 1137 | 0.160 |
Why?
| | Brain Chemistry | 1 | 2018 | 119 | 0.150 |
Why?
| | Medical History Taking | 1 | 2018 | 120 | 0.150 |
Why?
| | Bupropion | 1 | 2017 | 38 | 0.150 |
Why?
| | Drug Substitution | 1 | 2017 | 46 | 0.150 |
Why?
| | Comorbidity | 4 | 2017 | 1527 | 0.140 |
Why?
| | Volatile Organic Compounds | 1 | 2016 | 59 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2018 | 262 | 0.140 |
Why?
| | Community Mental Health Services | 2 | 2006 | 83 | 0.130 |
Why?
| | Internship and Residency | 1 | 2005 | 1006 | 0.130 |
Why?
| | Probability | 2 | 2006 | 305 | 0.130 |
Why?
| | Severity of Illness Index | 1 | 2023 | 2674 | 0.130 |
Why?
| | Patient Selection | 1 | 2018 | 675 | 0.120 |
Why?
| | Cooperative Behavior | 2 | 2006 | 408 | 0.120 |
Why?
| | Health Facilities | 1 | 2014 | 75 | 0.120 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2006 | 233 | 0.120 |
Why?
| | Veterans | 4 | 2017 | 1213 | 0.110 |
Why?
| | Treatment Outcome | 4 | 2022 | 9346 | 0.110 |
Why?
| | Follow-Up Studies | 4 | 2006 | 4596 | 0.110 |
Why?
| | Hospitals, Veterans | 4 | 2006 | 246 | 0.110 |
Why?
| | United States | 7 | 2017 | 12557 | 0.110 |
Why?
| | Neoplasms | 1 | 2006 | 2179 | 0.100 |
Why?
| | Mice | 3 | 2018 | 15528 | 0.100 |
Why?
| | Patient Care Team | 2 | 2006 | 522 | 0.100 |
Why?
| | Sucrose | 1 | 2012 | 104 | 0.100 |
Why?
| | Self Administration | 1 | 2012 | 125 | 0.100 |
Why?
| | Amphetamine-Related Disorders | 1 | 2011 | 28 | 0.100 |
Why?
| | Benzhydryl Compounds | 1 | 2011 | 60 | 0.100 |
Why?
| | Methamphetamine | 1 | 2011 | 51 | 0.100 |
Why?
| | Drug Interactions | 1 | 2012 | 352 | 0.090 |
Why?
| | Pilot Projects | 2 | 2005 | 1420 | 0.090 |
Why?
| | Ligands | 1 | 2012 | 567 | 0.090 |
Why?
| | Central Nervous System Stimulants | 1 | 2011 | 142 | 0.090 |
Why?
| | DNA Fingerprinting | 1 | 2009 | 26 | 0.090 |
Why?
| | Bacterial Typing Techniques | 1 | 2009 | 43 | 0.090 |
Why?
| | Baclofen | 1 | 2009 | 12 | 0.090 |
Why?
| | Genome, Bacterial | 1 | 2009 | 109 | 0.080 |
Why?
| | Intensive Care Units | 1 | 2013 | 635 | 0.080 |
Why?
| | Psychology | 2 | 2006 | 84 | 0.080 |
Why?
| | Calcium | 1 | 2014 | 1171 | 0.080 |
Why?
| | Temperance | 1 | 2007 | 15 | 0.080 |
Why?
| | DNA, Bacterial | 1 | 2009 | 314 | 0.080 |
Why?
| | Behavior Therapy | 2 | 2009 | 237 | 0.080 |
Why?
| | Liver | 2 | 2007 | 1816 | 0.080 |
Why?
| | Interpersonal Relations | 1 | 2010 | 345 | 0.080 |
Why?
| | Liver Failure | 1 | 2007 | 85 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2013 | 687 | 0.070 |
Why?
| | Liver Function Tests | 1 | 2007 | 107 | 0.070 |
Why?
| | Disease Management | 1 | 2010 | 571 | 0.070 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2006 | 135 | 0.070 |
Why?
| | Esters | 1 | 2006 | 61 | 0.070 |
Why?
| | Skull | 1 | 2006 | 127 | 0.070 |
Why?
| | Evolution, Molecular | 1 | 2009 | 454 | 0.070 |
Why?
| | Saliva | 1 | 2006 | 188 | 0.070 |
Why?
| | Carbamazepine | 1 | 2005 | 19 | 0.070 |
Why?
| | Education | 1 | 2005 | 105 | 0.060 |
Why?
| | History, 20th Century | 1 | 2006 | 281 | 0.060 |
Why?
| | Genomics | 1 | 2009 | 705 | 0.060 |
Why?
| | Aspartate Aminotransferases | 1 | 2004 | 95 | 0.060 |
Why?
| | Linear Models | 1 | 2007 | 827 | 0.060 |
Why?
| | Regression Analysis | 1 | 2006 | 984 | 0.060 |
Why?
| | Alanine Transaminase | 1 | 2004 | 152 | 0.060 |
Why?
| | Social Support | 1 | 2007 | 542 | 0.060 |
Why?
| | Practice Guidelines as Topic | 3 | 2006 | 1440 | 0.060 |
Why?
| | Aged | 3 | 2014 | 19661 | 0.060 |
Why?
| | Chi-Square Distribution | 1 | 2004 | 525 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2004 | 403 | 0.060 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 239 | 0.060 |
Why?
| | Minority Groups | 1 | 2005 | 237 | 0.060 |
Why?
| | Fatty Acids | 1 | 2006 | 407 | 0.060 |
Why?
| | Survival Analysis | 1 | 2006 | 1267 | 0.050 |
Why?
| | Prospective Studies | 2 | 2005 | 6477 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2006 | 1223 | 0.050 |
Why?
| | Quality of Life | 2 | 2020 | 2369 | 0.050 |
Why?
| | Combined Modality Therapy | 3 | 2011 | 1167 | 0.050 |
Why?
| | Drug Monitoring | 1 | 2003 | 187 | 0.050 |
Why?
| | United States Department of Veterans Affairs | 1 | 2005 | 555 | 0.050 |
Why?
| | Motivation | 1 | 2005 | 506 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2013 | 12990 | 0.050 |
Why?
| | Guideline Adherence | 1 | 2005 | 523 | 0.050 |
Why?
| | Health Status | 1 | 2005 | 726 | 0.050 |
Why?
| | Outpatients | 1 | 2003 | 325 | 0.050 |
Why?
| | Risk Factors | 3 | 2013 | 9003 | 0.040 |
Why?
| | Curriculum | 1 | 2005 | 910 | 0.040 |
Why?
| | Reducing Agents | 1 | 2016 | 4 | 0.040 |
Why?
| | Time Factors | 2 | 2006 | 6414 | 0.040 |
Why?
| | Remission Induction | 1 | 2017 | 247 | 0.040 |
Why?
| | Drug Resistance | 1 | 2017 | 167 | 0.040 |
Why?
| | Drug Synergism | 1 | 2017 | 339 | 0.040 |
Why?
| | Substance-Related Disorders | 1 | 2005 | 971 | 0.040 |
Why?
| | Case Management | 2 | 2006 | 63 | 0.030 |
Why?
| | Oxidants | 1 | 2016 | 122 | 0.030 |
Why?
| | Sodium Chloride | 1 | 2016 | 144 | 0.030 |
Why?
| | Health Services Accessibility | 3 | 2006 | 781 | 0.030 |
Why?
| | Health Plan Implementation | 2 | 2006 | 133 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3175 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 536 | 0.030 |
Why?
| | Patient Readmission | 2 | 2013 | 633 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 965 | 0.030 |
Why?
| | Taste | 1 | 2016 | 218 | 0.030 |
Why?
| | Rheology | 1 | 2014 | 87 | 0.030 |
Why?
| | Solubility | 1 | 2014 | 235 | 0.030 |
Why?
| | Continuity of Patient Care | 2 | 2006 | 265 | 0.030 |
Why?
| | Self Care | 2 | 2006 | 357 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 940 | 0.030 |
Why?
| | Cost-Benefit Analysis | 2 | 2006 | 554 | 0.030 |
Why?
| | Patient Education as Topic | 2 | 2006 | 699 | 0.020 |
Why?
| | Patient Dropouts | 1 | 2011 | 66 | 0.020 |
Why?
| | Psychotherapy, Group | 1 | 2011 | 61 | 0.020 |
Why?
| | Chronic Disease | 2 | 2006 | 1637 | 0.020 |
Why?
| | DNA Restriction-Modification Enzymes | 1 | 2009 | 1 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2009 | 28 | 0.020 |
Why?
| | Survivors | 1 | 2013 | 418 | 0.020 |
Why?
| | Cohort Studies | 2 | 2013 | 5117 | 0.020 |
Why?
| | GABA Agonists | 1 | 2009 | 19 | 0.020 |
Why?
| | Food Microbiology | 1 | 2009 | 59 | 0.020 |
Why?
| | Limbic System | 1 | 2009 | 42 | 0.020 |
Why?
| | Multigene Family | 1 | 2009 | 200 | 0.020 |
Why?
| | Placebos | 1 | 2009 | 202 | 0.020 |
Why?
| | Employment | 1 | 2009 | 135 | 0.020 |
Why?
| | Safety | 1 | 2009 | 304 | 0.020 |
Why?
| | Educational Status | 1 | 2009 | 437 | 0.020 |
Why?
| | Medication Adherence | 1 | 2011 | 556 | 0.020 |
Why?
| | Counseling | 1 | 2009 | 353 | 0.020 |
Why?
| | Calibration | 1 | 2006 | 135 | 0.020 |
Why?
| | Pensions | 1 | 2005 | 4 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2005 | 38 | 0.020 |
Why?
| | Public Sector | 1 | 2005 | 18 | 0.020 |
Why?
| | Personality Assessment | 1 | 2005 | 78 | 0.020 |
Why?
| | Combat Disorders | 1 | 2005 | 34 | 0.020 |
Why?
| | Interview, Psychological | 1 | 2005 | 93 | 0.020 |
Why?
| | Cross-Sectional Studies | 2 | 2005 | 4552 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2005 | 307 | 0.010 |
Why?
| | California | 1 | 2005 | 382 | 0.010 |
Why?
| | Disability Evaluation | 1 | 2005 | 280 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 2874 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2005 | 482 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1795 | 0.010 |
Why?
| | Indians, North American | 1 | 2005 | 598 | 0.010 |
Why?
| | Age Factors | 1 | 2005 | 2995 | 0.010 |
Why?
| | Hospitalization | 1 | 2005 | 1785 | 0.010 |
Why?
|
|
Beresford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|